iCorMicA-An International Clinical Trial for Stratified Medicine in Angina

Published: 27 October 2022

Professor Colin Berry is leading the iCorMicA study, an international clinical trial for stratified medicine in angina, across the UK and Europe

profile

Prof. Colin Berry is leading the iCorMicA study, an international clinical trial for stratified medicine in angina, across the UK and Europe. The iCorMicA study builds on the success of the pilot trial CorMicA that was supported by a BHF Project Grand and BHF CoRE Fellowship to Dr Tom Ford.

The iCorMicA study is funded by Abbot and sponsored by both University of Glasgow and NHS GG&C. It is a multicentre, prospective, randomised, double-blind, sham-controlled, parallel-group, end-point trial and registry. The investigators seek to determine whether stratified medical therapy guided by an adjunctive interventional diagnostic procedure (IDP) during the invasive management of patients with known or suspected angina, but no obstructive coronary artery disease improves symptoms, wellbeing, cardiovascular risk and clinical outcomes.

Image of a map

Thanks to the hard work of the team from Glasgow and the collaborating sites, there have been 20 sites in the UK and two sites in the Republic of Ireland, as demonstrated in the map, open to patient enrolment. As of 26th October 2022, 217 patients have been randomized. Meanwhile, the Glasgow team is committed to expand the iCorMicA footprint in Europe. Collective efforts by the sponsors and funder are ongoing, with a projected involvement of 2-4 further countries. 


First published: 27 October 2022